Inflammatory myofibroblastic tumor is a neoplasia of unknown clinical etiology that clinically and radiologically tends to mimic a malignant neoplasm. The tumor is histologically composed of a mixture of inflammatory cells, myofibroblastic spindle cells and plasma cells. It can occur in any part of the body. Although pulmonary inflammatory myofibroblastic tumor is the most common primary lung mass especially in childhood, this entity is usually not considered in differential diagnosis of lung nodules or masses. In this article, we aimed to disscus the pathology and imaging findings of the pulmonary inflammatory myofibroblastic tumor and increase the familiarity of radiologists and clinicians to this entity.

Amaç: Bu çalışmanın amacı, yüzün altı farklı bölgesinin epidermis, dermis ve toplam deri kalınlıklarının belirlenerek cilt kalınlığı haritası oluşturmaktır. Hastalar ve Yöntem: Yaşları 30-80 arasında değişen 90 kadın ve 90 erkek hastanın yüz derisi, saçlı deri, alın, yanak, kulak, burun ve dudak bölgelerinden 9-10 mm sağlıklı doku içeren örnekler retrospektif olarak çalışmaya dahil edildi. Örnekler incelendi ve ışık mikroskobu altında mikrometre ile epidermis ve dermis kalınlıkları ölçüldü. Bulgular: Çalışmaya alınan 90 kadın katılımcının 6 yüz bölgesinin epidermis kalınlıkları 65,91±14,44 μm ile 120,91 ±44,74 μm, dermis kalınlıkları 1150±217,43 μm ile 1498,33±388,56 μm ve toplam deri kalınlıkları 1234,83± 217,6 μm ve 1599,33±492,2 μm idi. Çalışmaya alınan 90 erkek katılımcının 6 yüz bölgesinin epidermis kalınlıkları 79,08±13,88 μm ile 122,75±32,5 μm, dermis kalınlıkları 1106,66±389,82 μm ile 1942,5±464,06 μm ve toplam deri kalınlıkları 1756±503,75 μm ve 2022,5±460,24 μm arasında bulundu. Sonuç: Kadın hastalarda en ince epidermis saçlı deriden, erkek hastalarda ise en ince epidermis yanaktan ölçüldü. En kalın epidermis kadın ve erkek hastalarda üst dudak üstü bölgedeydi. Ancak dermis kalınlığının en ince ve kalın olduğu bölgeler cinsiyete göre farklılık gösterdi. Daha ileri çalışmalarda, daha çok merkezli, çok ırklı materyaller kullanılarak yüzün daha fazla alt birime bölünmesiyle yüz derisi kalınlığının tam bir haritası elde edilebilir.

Objectives: This study aimed to investigate the relationship between patients with and without extraglandular involvement in Sjögren's syndrome (SS) by analyzing ANA (antinuclear antibody) and ENA (extractable nuclear antigen) results and minor salivary gland pathology findings. Patients and methods: A total of 265 (245 females; 20 males; mean age: 50.4±12.4; range, 19 to 79 years) patients diagnosed with SS were included in the retrospective cohort study between March 1, 2011, and December 1, 2021. Detailed documentation was performed, capturing demographic characteristics, clinical information, laboratory findings, medication usage, and manifestations of the syndrome. The patients were divided into two groups, with (78 females; 8 males; mean age: 52.7±11.5; range, 22 to 78 years or without (167 females; 12 males; mean age: 49.3±12.8; range, 19 to 79 years extraglandular involvement. Results: The mean follow-up duration was 63.1±31.9 months. Extraganular involvement, including joint involvement, lung involvement, central nervous system involvement, hematological involvement, hepatitis, and lymphoma, was observed in 32.5% of the patients. Patients with extraglandular involvement required multiple medications, while those with only glandular involvement predominantly used hydroxychloroquine. The mean duration from SS diagnosis to extraglandular involvement was 15.2±27.8 months. The comparison between patients with and without extraglandular involvement revealed a significant association between higher focus scores (FS) and extraglandular manifestations. However, no significant differences were observed in terms of ANA positivity, ANA titers, or ENA positivity. Regression analysis indicated that age and FS were linked to systemic involvement. Conclusion: This study highlights the importance of FS as a predictive indicator for extraglandular manifestations in SS. Advanced age was found to be associated with an increased likelihood of extraglandular involvement. Assessing FS and age can aid in predicting extraglandular manifestations.